Royalty Pharma plc (RPRX) Reports Q2 Revenue of $555 Million
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $58.41 -0.88%
Financial Fact:
Research and development: 3.18M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
Research and development: 3.18M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q2 revenue of $555 million, versus $511 million reported last year.
- Increased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 million
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Corpay agrees to $100M FTC settlement over marketing practices
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
